The PTEN-PI3K pathway: Of feedbacks and cross-talks

Oncogene

Volumn 27, Issue 41, 2008, Pages 5527-5541

  Carracedo, A ^a   Pandolfi, P P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cross talk; Drug combination; Feedback; PI3K; PTEN

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ANTINEOPLASTIC AGENT; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; SF 1126; TEMSIROLIMUS; UNCLASSIFIED DRUG; WORTMANNIN; XL 147; XL 765;

BREAST CANCER; CELL GROWTH; CELL METABOLISM; CELL SURVIVAL; COLORECTAL CANCER; ENZYME ACTIVATION; ENZYME ACTIVITY; FEEDBACK SYSTEM; GENETIC TRANSDUCTION; HUMAN; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR SUPPRESSOR GENE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; FEEDBACK, BIOCHEMICAL; HUMANS; MODELS, BIOLOGICAL; PTEN PHOSPHOHYDROLASE; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION;

EID: 51849084360     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.247     Document Type: Review

References (188)

1. Ahn Y, Hwang CY, Lee SR, Kwon KS, Lee C. (2008). Tumor suppressor PTEN mediates a negative regulation of E3 ubiquitin-protein ligase Nedd4. Biochem J 412: 331-338.
2. Albuquerque C, Breukel C, van der Luijt R, Fidalgo P, Lage P, Slors FJ et al. (2002). The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum Mol Genet 11: 1549-1560.
3. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB et al. (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7: 261-269.
4. Almind K, Inoue G, Pedersen O, Kahn CR. (1996). A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest 97: 2569-2575.
5. Ashcroft M, Ludwig RL, Woods DB, Copeland TD, Weber HO, MacRae EJ et al. (2002). Phosphorylation of HDM2 by Akt. Oncogene 21: 1955-1962.
6. Backer JM. (2008). The regulation and function of class III PI3Ks: novel roles for Vps34. Biochem J 410: 1-17.
7. Bader AG, Kang S, Zhao L, Vogt PK. (2005). Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5: 921-929.
8. Bai X, Ma D, Liu A, Shen X, Wang QJ, Liu Y et al. (2007). Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 318: 977-980.
9. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM. (2005). Increased p85/55/50 expression and decreased phosphotidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes 54: 2351-2359.
10. Barber DF, Alvarado-Kristensson M, Gonzalez-Garcia A, Pulido R, Carrera AC. (2006). PTEN regulation, a novel function for the p85 subunit of phosphoinositide 3-kinase. Sci STKE 2006: pe49.
11. Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A et al. (2008). TGF-beta signalling-related markers in cancer patients with bone metastasis. Biomarkers 13: 217-236.
12. Bayascas JR, Alessi DR. (2005). Regulation of Akt/PKB Ser473 phosphorylation. Mol Cell 18: 143-145.
13. Beck SE, Carethers JM. (2007). BMP suppresses PTEN expression via RAS/ERK signaling. Cancer Biol Ther 6: 1313-1317.
14. Berg CE, Lavan BE, Rondinone CM. (2002). Rapamycin partially prevents insulin resistance induced by chronic insulin treatment. Biochem Biophys Res Commun 293: 1021-1027.
15. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J et al. (2006). PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 442: 779-785.
16. Biggs III WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. (1999). Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA 96: 7421-7426.
17. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
18. Burgering BM. (2008). A brief introduction to FOXOlogy. Oncogene 27: 2258-2262.
19. Cantley LC. (2002). The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
20. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM et al. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439-444.
21. Carracedo A, Ma L, T eruya-Feldstein L, Rojo F, Salmena L, Alimonti A et al. (2008). Inhibition of mTORC1 leads to MAPK pathway activation through a P13K-dependent feedback loop in human cancer. J Clin Invest (in press).
22. Carracedo A, Salmena L, Pandolfi PP. (2008). SnapShot: PTEN signaling pathways. Cell 133: 550el.
23. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ et al. (1996). Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84: 491-495.
24. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M et al. (2005). Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725-730.
25. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S et al. (2008). Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5: e8.
26. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789.
27. Culjkovic B, Tan K, Orolicki S, Amri A, Meloche S, Borden KL. (2008). The eIF4E RNA regulon promotes the Akt signaling pathway. J Cell Biol 181: 51-63.
28. D'Alfonso R, Marini MA, Frittitta L, Sorge R, Frontoni S, Porzio O et al. (2003). Polymorphisms of the insulin receptor substrate-2 in patients with type 2 diabetes. J Clin Endocrinol Metab 88: 317-322.
29. Dan HC, Sun M, Yang L, Feldman RI, Sui XM, Ou CC et al. (2002). Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 277: 35364-35370.
30. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. (1997). Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278: 687-689.
31. Denley A, Kang S, Karst U, Vogt PK. (2008). Oncogenic signaling of class I PI3K isoforms. Oncogene 27: 2561-2574.
32. Denning G, Jean-Joseph B, Prince C, Durden DL, Vogt PK. (2007). A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth. Oncogene 26: 3930-3940.
33. Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. (1999). Impaired Fas response and autoimmunity in Pten+/- mice. Science 285: 2122-2125.
34. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. (1998). Pten is essential for embryonic development and tumour suppression. Nat Genet 19: 348-355.
35. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. (2006). S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314: 467-471.
36. Du K, Herzig S, Kulkarni RN, Montminy M. (2003). TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300: 1574-1577.
37. Endersby R, Baker SJ. (2008). PTEN Signaling in Brain: Neuropathology and Tumorigenesis. Oncogene (in press).
38. Eng C. (2003). PTEN: one gene, many syndromes. Hum Mutat 22: 183-198.
39. Engelman JA, Luo J, Cantley LC. (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619.
40. Esposito DL, Li Y, Vanni C, Mammarella S, Veschi S, Della Loggia F et al. (2003). A novel T608R missense mutation in insulin receptor substrate-1 identified in a subject with type 2 diabetes impairs metabolic insulin signaling. J Clin Endocrinol Metab 88: 1468-1475.
41. Faivre S, Kroemer G, Raymond E. (2006). Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688.
42. Fivaz M, Bandara S, Inoue T, Meyer T. (2008). Robust neuronal symmetry breaking by Ras-triggered local positive feedback. Curr Biol 18: 44-50.
43. Fraser MM, Bayazitov IT, Zakharenko SS, Baker SJ. (2008). Phosphatase and tensin homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic structure, transmission and plasticity, and myelination abnormalities. Neuroscience 151: 476-488.
44. Fraser MM, Zhu X, Kwon CH, Uhlmann EJ, Gutmann DH, Baker SJ. (2004). Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res 64: 7773-7779.
45. Fujita N, Sato S, Katayama K, Tsuruo T. (2002). Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 277: 28706-28713.
46. Funamoto S, Meili R, Lee S, Parry L, Firtel RA. (2002). Spatial and temporal regulation of 3-phosphoinositides by PI 3-kinase and PTEN mediates chemotaxis. Cell 109: 611-623.
47. Gao T, Furnari F, Newton AC. (2005). PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18: 13-24.
48. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H et al. (2003). Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11: 1457-1466.
49. Garcia-Echeverria C, Sellers W. (2008). Drug discovery approaches to target the P13K/Akt pathway in cancer cells. Oncogene (in press).
50. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A et al. (2008). A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 68: 206-215.
51. George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC et al. (2004). A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304: 1325-1328.
52. Ghilardi N, Ziegler S, Wiestner A, Stoffel R, Heim MH, Skoda RC. (1996). Defective STAT signaling by the leptin receptor in diabetic mice. Proc Natl Acad Sci USA 93: 6231-6235.
53. Greene MW, Sakaue H, Wang L, Alessi DR, Roth RA. (2003). Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by serine 312 phosphorylation. J Biol Chem 278: 8199-8211.
54. Gu J, Tamura M, Yamada KM. (1998). Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol 143: 1375-1383.
55. Guan KL, Figueroa C, Brtva TR, Zhu T, Taylor J, Barber TD et al. (2000). Negative regulation of the serine/threonine kinase B-Raf by Akt. J Biol Chem 275: 27354-27359.
56. Guertin DA, Sabatini DM. (2007). Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
57. Gulati P, Gaspers LD, Dann SG, Joaquin M, Nobukuni T, Natt F et al. (2008). Amino acids activate mTOR complex 1 via Ca(2+)/CaM signaling to hVps34. Cell Metab 7: 456-465.
58. Guo S, Rena G, Cichy S, He X, Cohen P, Unterman T. (1999). Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. J Biol Chem 274: 17184-17192.
59. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B et al. (2007). Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129: 957-968.
60. Han S, Ritzenthaler JD, Zheng Y, Roman J. (2008). PPAR{beta}/{delta} agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3-K and NF-{kappa}B signals. Am J Physiol Lung Cell Mol Physio 294: L1238-L1249.
61. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H et al. (2004). The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166: 213-223.
62. Hartley D, Cooper GM. (2002). Role of mTOR in the degradation of IRS-1: regulation of PP2A activity. J Cell Biochem 85: 304-314.
63. Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM et al. (2000). A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 14: 783-794.
64. Harvey RD, Lonial S. (2007). PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol 3: 639-647.
65. Herman PK, Emr SD. (1990). Characterization of VPS34, a gene required for vacuolar protein sorting and vacuole segregation in Saccharomyces cerevisiae. Mol Cell Biol 10: 6742-6754.
66. Hettinger K, Vikhanskaya F, Poh MK, Lee MK, de Belle I, Zhang JT et al. (2007). c-Jun promotes cellular survival by suppression of PTEN. Cell Death Differ 14: 218-229.
67. Huang J, Dibble CC, Matsuzaki M, Manning BD. (2008). The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 12: 4104-4115.
68. Im E, von Lintig FC, Chen J, Zhuang S, Qui W, Chowdhury S et al. (2002). Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene 21: 6356-6365.
69. Inoki K, Li Y, Xu T, Guan KL. (2003). Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17: 1829-1834.
70. Inoki K, Li Y, Zhu T, Wu J, Guan KL. (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648-657.
71. Jakobsen SN, Hardie DG, Morrice N, Tornqvist HE. (2001). 5′-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside. J Biol Chem 276: 46912-46916.
72. Jozwiak J, Jozwiak S, Wlodarski P. (2008). Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol 9: 73-79.
73. Karbowniczek M, Cash T, Cheung M, Robertson GP, Astrinidis A, Henske EP. (2004). Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J Biol Chem 279: 29930-29937.
74. Karbowniczek M, Robertson GP, Henske EP. (2006). Rheb inhibits Craf activity and B-raf/C-raf heterodimerization. J Biol Chem 281: 25447-25456.
75. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. (2001). Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615-675.
76. Kawanishi M, Tamori Y, Masugi J, Mori H, Ito C, Hansen T et al. (1997). Prevalence of a polymorphism of the phosphatidylinositol 3-kinase p85 alpha regulatory subunit (codon 326 Met → Ile) in Japanese NIDDM patients. Diabetes Care 20: 1043.
77. Kim MS, Jeong EG, Yoo NJ, Lee SH. (2008). Mutational analysis of oncogenic AKTE17K mutation in common solid cancers and acute leukaemias. Br J Cancer 118: 1700-1711.
78. Kim S, Domon-Dell C, Kang J, Chung DH, Freund JN, Evers BM. (2004). Down-regulation of the tumor suppressor PTEN by the tumor necrosis factor-alpha/nuclear factor-kappaB (NF-kappaB)-inducing kinase/NF-kappaB pathway is linked to a default IkappaB-alpha autoregulatory loop. J Biol Chem 279: 4285-4291.
79. Knudson AG. (1996). Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 122: 135-140.
80. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, Burgering BM. (1999). Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398: 630-634.
81. Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, Birnbaum MJ et al. (2003). Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem 278: 10189-10194.
82. Kurlawalla-Martinez C, Stiles B, Wang Y, Devaskar SU, Kahn BB, Wu H. (2005). Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissue. Mol Cell Biol 25: 2498-2510.
83. Lahlou H, Saint-Laurent N, Esteve JP, Eychene A, Pradayrol L, Pyronnet S et al. (2003). sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 278: 39356-39371.
84. Lee JT, Steelman LS, Chappell WH, McCubrey JA. (2008). Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells. Cell Cycle 7: 631-636.
85. Li DM, Sun H. (1997). TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57: 2124-2129.
86. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
87. Lindsay Y, McCoull D, Davidson L, Leslie NR, Fairservice A, Gray A et al. (2006). Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. J Cell Sci 119: 5160-5168.
88. Liu JL, Mao Z, LaFortune TA, Alonso MM, Gallick GE, Fueyo J et al. (2007). Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res 67: 11054-11063.
89. Lopiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. (2007). Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11: 32-50.
90. Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC. (2005a). The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J Cell Biol 170: 455-464.
91. Luo J, Manning BD, Cantley LC. (2003). Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4: 257-262.
92. Luo J, Sobkiw CL, Logsdon NM, Watt JM, Signoretti S, O'Connell F et al. (2005b). Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc Natl Acad Sci USA 102: 10238-10243.
93. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. (2005a). Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121: 179-193.
94. Ma L, Teruya-Feldstein J, Behrendt N, Chen Z, Noda T, Hino O et al. (2005b). Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev 19: 1779-1786.
95. Ma L, Teruya-Feldstein J, Bonner P, Bernardi R, Franz DN, Witte D et al. (2007). Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res 67: 7106-7112.
96. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y et al. (2002). Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 277: 33490-33500.
97. Maehama T, Dixon JE. (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378.
98. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM et al. (2004). mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10: 594-601.
99. Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q et al. (2003). Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci USA 100: 7841-7846.
100. Malanga D, Scrima M, De Marco C, Fabiani F, De Rosa N, De Gisi S et al. (2008). Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 7: 665-669.
101. Manning BD. (2004). Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 167: 399-403.
102. Manning BD, Cantley LC. (2007). AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
103. Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC. (2005). Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 19: 1773-1778.
104. Mayo LD, Donner DB. (2001). A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98: 11598-11603.
105. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. (2002). Regulation of Raf-Akt cross-talk. J Biol Chem 277: 31099-31106.
106. Nakae J, Park BC, Accili D. (1999). Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a wortmannin-sensitive pathway. J Biol Chem 274: 15982-15985.
107. Ni YG, Wang N, Cao DJ, Sachan N, Morris DJ, Gerard RD et al. (2007). FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases. Proc Natl Acad Sci USA 104: 20517-20522.
108. Nobukuni T, Joaquin M, Roccio M, Dann SG, Kim SY, Gulati P et al. (2005). Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci USA 102: 14238-14243.
109. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
110. Ozcan U, Ozcan L, Yilmaz E, Duvel K, Sahin M, Manning BD et al. (2008). Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 29: 541-551.
111. Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE et al. (2001). A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci USA 98: 4640-4645.
112. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M et al. (2007). Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 13: 1203-1210.
113. Papakonstanti EA, Ridley AJ, Vanhaesebroeck B. (2007). The p110delta isoform of PI 3-kinase negatively controls RhoA and PTEN. EMBO J 26: 3050-3061.
114. Pirola L, Bonnafous S, Johnston AM, Chaussade C, Portis F, Van Obberghen E. (2003). Phosphoinositide 3-kinase-mediated reduction of insulin receptor substrate-1/2 protein expression via different mechanisms contributes to the insulin-induced desensitization of its signaling pathways in L6 muscle cells. J Biol Chem 27815641-15651.
115. Potter CJ, Pedraza LG, Xu T. (2002). Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4: 658-665.
116. Radimerski T, Montagne J, Hemmings-Mieszczak M, Thomas G. (2002). Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. Genes Dev 16: 2627-2632.
117. Ramjaun AR, Downward J. (2007). Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis. Cell Cycle 6: 2902-2905.
118. Raught B, Peiretti F, Gingras AC, Livingstone M, Shahbazian D, Mayeur GL et al. (2004). Phosphorylation of eukaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J 23: 1761-1769.
119. Rena G, Guo S, Cichy SC, Unterman TG, Cohen P. (1999). Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem 274: 17179-17183.
120. Reusch HP, Zimmermann S, Schaefer M, Paul M, Moelling K. (2001). Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells. J Biol Chem 276: 33630-33637.
121. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P et al. (1997). Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89: 457-467.
122. Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K et al. (1999). Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286: 1738-1741.
123. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. (2004). Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 101: 13489-13494.
124. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J et al. (2007). RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282: 14056-14064.
125. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. (1994). RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78: 35-43.
126. Salmena L, Carracedo A, Pandolfi PP. (2008). Tenets of PTEN tumor suppression. Cell 133: 403-414.
127. Sampaio C, Dance M, Montagner A, Edouard T, Malet N, Perret B et al. (2008). Signal strength dictates phosphoinositide 3-kinase contribution to Ras/extracellular signal-regulated kinase 1 and 2 activation via differential Gab1/Shp2 recruitment: consequences for resistance to epidermal growth factor receptor inhibition. Mol Cell Biol 28: 587-600.
128. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
129. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E et al. (2007). PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25: 903-915.
130. Sano H, Kane S, Sano E, Miinea CP, Asara JM, Lane WS et al. (2003). Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem 278: 14599-14602.
131. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H et al. (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302.
132. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
133. Sasaki AT, Chun C, Takeda K, Firtel RA. (2004). Localized Ras signaling at the leading edge regulates PI3K, cell polarity, and directional cell movement. J Cell Biol 167: 505-518.
134. Sasaki AT, Janetopoulos C, Lee S, Charest PG, Takeda K, Sundheimer LW et al. (2007). G protein-independent Ras/PI3K/F-actin circuit regulates basic cell motility. J Cell Biol 178: 185-191.
135. Sato S, Fujita N, Tsuruo T. (2004). Involvement of 3-phosphoinositide- dependent protein kinase-1 in the MEK/MAPK signal transduction pathway. J Biol Chem 279: 33759-33767.
136. Schafer B, Gschwind A, Ullrich A. (2004). Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 23: 991-999.
137. Schwindinger WF, Robishaw JD. (2001). Heterotrimeric G-protein betagamma-dimers in growth and differentiation. Oncogene 20: 1653-1660.
138. Shah OJ, Wang Z, Hunter T. (2004). Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14: 1650-1656.
139. Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J et al. (2006). The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 25: 2781-2791.
140. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T et al. (1998). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39.
141. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362.
142. Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim YJ et al. (2004). Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci USA 101: 2082-2087.
143. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al. (2005). Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65: 7052-7058.
144. Takaishi H, Konishi H, Matsuzaki H, Ono Y, Shirai Y, Saito N et al. (1999). Regulation of nuclear translocation of forkhead transcription factor AFX by protein kinase B. Proc Natl Acad Sci USA 96: 11836-11841.
145. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L et al. (2008). Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111: 379-382.
146. Tang ED, Nunez G, Barr FG, Guan KL. (1999). Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 274: 16741-16746.
147. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. (2003). Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 13: 1259-1268.
148. Torres J, Pulido R. (2001). The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 276: 993-998.
149. Tremblay F, Brule S, Hee Um S, Li Y, Masuda K, Roden M et al. (2007). Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci USA 104: 14056-14061.
150. Tremblay F, Marette A. (2001). Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem 276: 38052-38060.
151. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. (2006). Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441: 523-527.
152. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H et al. (2007). Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128: 141-156.
153. Tzatsos A, Kandror KV. (2006). Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 26: 63-76.
154. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. (2007). Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9: 316-323.
155. Vasudevan KM, Burikhanov R, Goswami A, Rangnekar VM. (2007). Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras. Cancer Res 67: 10343-10350.
156. Vasudevan KM, Gurumurthy S, Rangnekar VM. (2004). Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol 24: 1007-1021.
157. Vezina C, Kudelski A, Sehgal SN. (1975). Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 28: 721-726.
158. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ et al. (2007). Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 11: 555-569.
159. Vivanco I, Sawyers CL. (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
160. Walker SM, Leslie NR, Perera NM, Batty IH, Downes CP. (2004). The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem J 379: 301-307.
161. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. (2007). Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932-1940.
162. Wang Q, Zhou Y, Wang X, Evers BM. (2006). Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase. Oncogene 25: 43-50.
163. Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG. (2001). Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 20: 4370-4379.
164. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z et al. (2007). NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128: 129-139.
165. Weinstein IB, Joe A. (2008). Oncogene addiction. Cancer Res 68: 3077-3080. (discussion 3080)
166. Welch HC, Coadwell WJ, Stephens LR, Hawkins PT. (2003). Phosphoinositide 3-kinase-dependent activation of Rac. FEBS Lett 546: 93-97.
167. Wells V, Downward J, Mallucci L. (2007). Functional inhibition of PI3K by the betaGBP molecule suppresses Ras-MAPK signalling to block cell proliferation. Oncogene 26: 7709-7714.
168. Wennstrom S, Downward J. (1999). Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol Cell Biol 19: 4279-4288.
169. Wijesekara N, Konrad D, Eweida M, Jefferies C, Liadis N, Giacca A et al. (2005). Muscle-specific Pten deletion protects against insulin resistance and diabetes. Mol Cell Biol 25: 1135-1145.
170. Wu DN, Pei DS, Wang Q, Zhang GY. (2006). Down-regulation of PTEN by sodium orthovanadate inhibits ASK1 activation via PI3-K/Akt during cerebral ischemia in rat hippocampus. Neurosci Lett 404: 98-102.
171. Wu W, Wang X, Zhang W, Reed W, Samet JM, Whang YE et al. (2003). Zinc-induced PTEN protein degradation through the proteasome pathway in human airway epithelial cells. J Biol Chem 278: 28258-28263.
172. Xia D, Srinivas H, Ahn YH, Sethi G, Sheng X, Yung WK et al. (2007). Mitogen-activated protein kinase kinase-4 promotes cell survival by
173. Yart A, Chap H, Raynal P. (2002). Phosphoinositide 3-kinases in lysophosphatidic acid signaling: regulation and cross-talk with the Ras/mitogen-activated protein kinase pathway. Biochim Biophys Acta 1582: 107-111.
174. Yart A, Laffargue M, Mayeux P, Chretien S, Peres C, Tonks N et al. (2001). A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor. J Biol Chem 276: 8856-8864.
175. Yee WM, Worley PF. (1997). Rheb interacts with Raf-1 kinase and may function to integrate growth factor- and protein kinase A-dependent signals. Mol Cell Biol 17: 921-933.
176. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H et al. (2006). Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441: 475-482.
177. Yuan TL, Cantley LC. (2008). P13K pathway alterations in cancer: variations on a theme. Oncogene (in press).
178. Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ. (2003). AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem 278: 23432-23440.
179. Zhande R, Mitchell JJ, Wu J, Sun XJ. (2002). Molecular mechanism of insulin-induced degradation of insulin receptor substrate 1. Mol Cell Biol 22: 1016-1026.
180. Zhang BH, Tang ED, Zhu T, Greenberg ME, Vojtek AB, Guan KL. (2001). Serum- and glucocorticoid-inducible kinase SGK phosphorylates and negatively regulates B-Raf. J Biol Chem 276: 31620-31626.
181. Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL et al. (2007). PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 117: 730-738.
182. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N et al. (2003a). Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 112: 1223-1233.
183. Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD. (2006a). S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell 24: 185-197.
184. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT et al. (2006b). PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441: 518-522.
185. Zhang R, Luo D, Miao R, Bai L, Ge Q, Sessa WC et al. (2005). Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene 24: 3954-3963.
186. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. (2003b). Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5: 578-581.
187. Zhao L, Vogt PK. (2008). Class I P13K in oncogenic cellular transformation. Oncogene (in press).
188. Zimmermann S, Moelling K. (1999). Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286: 1741-1744.